325.03

0.36% 1.18

Insulet Corporation (PODD)

Overview News Price History Option Chain Financials Why PODD Down? Discussions Forecast

Insulet Corporation stock is traded at $325.03, with a volume of 960.66K. It is up +0.36% in the last 24 hours and up +29.35% over the past month. Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.

Previous Close:

$323.85

Open:

$324.22

24h Volume:

960.66K

Relative Volume:

1.11

Market Cap:

$22.88B

Revenue:

$2.20B

Net Income/Loss:

$402.20M

P/E Ratio:

58.46

EPS:

5.56

Net Cash Flow:

$280.80M

1W Performance:

+1.14%

1M Performance:

+29.35%

6M Performance:

+21.83%

1Y Performance:

+84.73%

1-Day Range:

$320.71

$326.24

1-Week Range:

$320.71

$329.10

52-Week Range:

$172.07

$329.33

Insulet Corporation Stock (PODD) Company Profile

Name

Insulet Corporation

Sector

Healthcare (1170)

Industry

Medical Devices (155)

Phone

978-600-7000

Address

100 NAGOG PARK, ACTON, MA

Employee

3,900

Twitter

@insulet_uk

Next Earnings Date

2024-11-07

Latest SEC Filings

PODD's Discussions on Twitter

Compare PODD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PODD Insulet Corporation	325.03	22.62B	2.20B	402.20M	280.80M	5.56
ABT Abbott Laboratories	133.58	228.44B	42.34B	13.50B	6.66B	7.71
BSX Boston Scientific Corp	105.26	154.60B	17.55B	2.03B	2.72B	1.37
SYK Stryker Corp	382.64	143.93B	23.22B	2.86B	3.58B	7.40
MDT Medtronic Plc	82.98	103.43B	33.54B	4.66B	5.19B	3.62
EW Edwards Lifesciences Corp	78.22	43.99B	5.54B	4.18B	623.10M	7.00

Insulet Corporation Stock (PODD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-13-25	Upgrade	Wolfe Research	Peer Perform → Outperform
Apr-29-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Mar-06-25	Initiated	RBC Capital Mkts	Outperform
Nov-06-24	Initiated	Bernstein	Outperform
May-30-24	Initiated	Redburn Atlantic	Buy
May-07-24	Upgrade	Wolfe Research	Peer Perform → Outperform
Dec-21-23	Upgrade	Robert W. Baird	Neutral → Outperform
Dec-04-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-02-23	Upgrade	Jefferies	Hold → Buy
Aug-21-23	Upgrade	Citigroup	Neutral → Buy
Aug-21-23	Downgrade	Robert W. Baird	Outperform → Neutral
May-30-23	Resumed	Morgan Stanley	Equal-Weight
Jan-26-23	Initiated	Wolfe Research	Peer Perform
Nov-04-22	Upgrade	Piper Sandler	Neutral → Overweight
Oct-18-22	Initiated	Barclays	Equal Weight
Oct-12-22	Initiated	Jefferies	Hold
Jul-11-22	Downgrade	Citigroup	Buy → Neutral
Mar-02-22	Resumed	BofA Securities	Buy
Feb-03-22	Upgrade	BTIG Research	Neutral → Buy
Feb-02-22	Upgrade	UBS	Neutral → Buy
Jan-31-22	Upgrade	Oppenheimer	Perform → Outperform
Jul-21-21	Resumed	Cowen	Outperform
May-25-21	Initiated	Barclays	Overweight
Apr-01-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Mar-19-21	Upgrade	Canaccord Genuity	Hold → Buy
Jan-29-21	Downgrade	Piper Sandler	Overweight → Neutral
Dec-16-20	Downgrade	Citigroup	Buy → Neutral
Jul-28-20	Initiated	Wells Fargo	Overweight
Apr-24-20	Downgrade	SVB Leerink	Outperform → Mkt Perform
Apr-03-20	Initiated	BofA/Merrill	Neutral
Mar-31-20	Downgrade	Berenberg	Buy → Hold
Mar-05-20	Initiated	Citigroup	Buy
Dec-10-19	Initiated	CFRA	Sell
Oct-23-19	Initiated	Stifel	Hold
Oct-18-19	Downgrade	Canaccord Genuity	Buy → Hold
Oct-14-19	Downgrade	BTIG Research	Buy → Neutral
Oct-04-19	Downgrade	UBS	Buy → Neutral
Oct-03-19	Downgrade	Guggenheim	Buy → Neutral
Aug-06-19	Upgrade	JP Morgan	Neutral → Overweight
Jun-10-19	Downgrade	Northland Capital	Outperform → Market Perform
May-06-19	Upgrade	BTIG Research	Neutral → Buy
Apr-20-18	Initiated	Berenberg	Buy
Feb-22-18	Reiterated	Barclays	Overweight
Jan-08-18	Upgrade	Raymond James	Mkt Perform → Outperform
Nov-03-17	Upgrade	Canaccord Genuity	Hold → Buy
Sep-15-17	Initiated	Barclays	Overweight

View All

Insulet Corporation Stock (PODD) Latest News

May 30, 2025

Goldman Sachs Initiates Coverage of Insulet (PODD) with Buy Recommendation - Nasdaq

May 30, 2025

Goldman Sachs Initiates Coverage on Insulet (PODD) with Buy Rati - GuruFocus

May 30, 2025

Goldman Sachs Initiates Coverage on Insulet (PODD) with a Buy Ra - GuruFocus

May 30, 2025

Goldman Sachs initiates coverage of medtech stocks Insulet and Dexcom at Buy - Investing.com

May 30, 2025

Goldman Sachs Initiates Insulet at Buy With $380 Price Target - marketscreener.com

May 30, 2025

Goldman Sachs starts Insulet stock with buy, $380 target - Investing.com

May 30, 2025

Goldman Sachs Starts Insulet Corporation (PODD) at Buy - StreetInsider

May 30, 2025

May 29, 2025

Goldman Sachs Initiates Coverage on Insulet (PODD) with Positive Outlook | PODD Stock News - GuruFocus

May 29, 2025

Insulet Corporation: Shares Remain Astronomically Expensive (NASDAQ:PODD) - Seeking Alpha

May 28, 2025

Insulet Corporation Holds 2025 Annual Stockholders Meeting - TipRanks

May 28, 2025

Is Insulet Corporation (NASDAQ:PODD) A High Quality Stock To Own? - Yahoo Finance

May 28, 2025

What Is Insulet Corporation's (NASDAQ:PODD) Share Price Doing? - simplywall.st

May 28, 2025

Here's How Much $100 Invested In Insulet 15 Years Ago Would Be Worth Today - Benzinga

May 28, 2025

Raymond James Increases Price Target for Insulet (PODD) to $360 - GuruFocus

May 28, 2025

May 27, 2025

Insulet Gains 78.5% in a Year: What's Driving the Stock? - MSN

May 27, 2025

Insulet (PODD) Target Price Raised by Raymond James | PODD Stock News - GuruFocus

May 27, 2025

Raymond James Increases Price Target for Insulet (PODD) to $360 | PODD Stock News - GuruFocus

May 27, 2025

Raymond James Adjusts Price Target on Insulet to $360 From $328, Maintains Outperform Rating - marketscreener.com

May 27, 2025

Insulet stock target lifted to $360 by Raymond James - Investing.com India

May 27, 2025